Compare CLBT & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLBT | INSP |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | N/A | 2018 |
| Metric | CLBT | INSP |
|---|---|---|
| Price | $18.23 | $94.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 17 |
| Target Price | $24.40 | ★ $137.63 |
| AVG Volume (30 Days) | 985.4K | ★ 1.9M |
| Earning Date | 02-12-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.77 |
| EPS | 0.31 | ★ 1.48 |
| Revenue | $455,903,000.00 | ★ $882,622,000.00 |
| Revenue This Year | $20.25 | $15.00 |
| Revenue Next Year | $17.24 | $11.24 |
| P/E Ratio | ★ $58.82 | $64.67 |
| Revenue Growth | ★ 18.36 | 16.81 |
| 52 Week Low | $13.10 | $70.77 |
| 52 Week High | $26.30 | $216.01 |
| Indicator | CLBT | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 37.45 |
| Support Level | $17.66 | $93.05 |
| Resistance Level | $19.39 | $97.10 |
| Average True Range (ATR) | 0.53 | 6.79 |
| MACD | -0.04 | -5.05 |
| Stochastic Oscillator | 32.95 | 7.76 |
Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze, and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.